Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Classement en actions #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Prix de l'action
$137.21
Capitalisation boursière
$170.34B
Changement (1 jour)
-2.76%
Changement (1 an)
28.14%
Pays
US
Échange Gilead Sciences, Inc. (GILD)

Catégorie

Revenus pour Gilead Sciences, Inc. (GILD)
Revenus en Dec 2025 TTM : $29.44B
Selon les derniers rapports financiers de Gilead Sciences, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $29.44B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $28.75B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $27.12B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Gilead Sciences, Inc. de 2000 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $29.44B 0.00%
2025 $29.44B 2.40%
2024 $28.75B 6.04%
2023 $27.12B -0.60%
2022 $27.28B -0.09%
2021 $27.31B 10.60%
2020 $24.69B 9.98%
2019 $22.45B 1.46%
2018 $22.13B -15.24%
2017 $26.11B -14.09%
2016 $30.39B -6.89%
2015 $32.64B 31.13%
2014 $24.89B 122.19%
2013 $11.20B 15.46%
2012 $9.70B 15.70%
2011 $8.39B 5.48%
2010 $7.95B 13.38%
2009 $7.01B 31.40%
2008 $5.34B 26.14%
2007 $4.23B 39.78%
2006 $3.03B 49.19%
2005 $2.03B 53.13%
2004 $1.32B 52.63%
2003 $867.86M 85.92%
2002 $466.79M 99.68%
2001 $233.77M 19.54%
2000 $195.56M 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
$65.18B 121.38%
US
$58.74B 99.51%
GB
$94.19B 219.93%
US
$61.16B 107.73%
US
$56.15B 90.71%
CH